Skip Ribbon Commands
Skip to main content
Navigate Up
Sign In
Charles S. Landis, MD, PhD
Associate Professor
Biography

Dr. Landis's expertise are in general and transplant hepatology, general gastroenterology and endoscopy. His research interests include hepatocellular carcinoma and new therapeutic agents for chronic hepatitis C.

Recent Publications
Displaying 20 Most Recent Publications from PubMed

May 2018. Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1. Bourlière M, Gordon SC, Schiff ER, Tran TT, Ravendhran N, Landis CS, Hyland RH, Stamm LM, Zhang J, Dvory-Sobol H, Subramanian GM, Brainard DM, McHutchison JG, Serfaty L, Thompson AJ, Sepe TE, Curry MP, Reddy KR, Manns MP. Lancet Gastroenterol Hepatol. 2018 May 30. pii: S2468-1253(18)30118-3. doi: 10.1016/S2468-1253(18)30118-3. [Epub ahead of print]

March 2018. Extracorporeal Cellular Therapy (ELAD) in Severe Alcoholic Hepatitis - A Multinational, Prospective, Controlled, Randomized Trial. Thompson J, Jones N, Al-Khafaji A, Malik S, Reich D, Munoz S, MacNicholas R, Hassanein T, Teperman L, Stein L, Duarte-Rojo A, Malik R, Adhami T, Asrani S, Shah N, Gaglio P, Duddempudi A, Borg B, Jalan R, Brown R, Patton H, Satoskar R, Rossi S, Parikh A, ElSharkawy A, Mantry P, Sher L, Wolf D, Hart M, Landis C, Wigg A, Habib S, McCaughan G, Colquhoun S, Henry A, Bedard P, Landeen L, Millis M, Ashley R, Frank W, Henry A, Stange J, Subramanian R; VTI-208 Study Group. Liver Transpl. 2018 Mar;24(3):380-393. doi: 10.1002/lt.24986.

January 2018. Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients with Genotype 1 Hepatitis C Virus Infection and Cirrhosis. Lim JK, Liapakis AM, Shiffman ML, Lok AS, Zeuzem S, Terrault NA, Park JS, Landis CS, Hassan M, Gallant J, Kuo A, Pockros PJ, Vainorius M, Akushevich L, Michael L, Fried MW, Nelson DR, Ben-Ari Z; HCV-TARGET Study Group. Clin Gastroenterol Hepatol. 2018 Jan 3. pii: S1542-3565(17)31535-5. doi: 10.1016/j.cgh.2017.12.037. [Epub ahead of print]

August 2017. Glecaprevir and Pibrentasvir for 12 Weeks for HCV Genotype 1 Infection and Prior Direct-acting Antiviral Treatment. Poordad F, Felizarta F, Asatryan A, Sulkowski MS, Reindollar RW, Landis CS, Gordon SC, Flamm SL, Fried MW, Bernstein DE, Lin CW, Liu R, Lovell SS, Ng TI, Kort J, Mensa FJ. Hepatology. 2017 Aug;66(2):389-397. doi: 10.1002/hep.29081. Epub 2017 Apr 10.

August 2017. Biopsies from Allograft Liver Contain Histologic Features of Hepatitis C Virus Infection Following Virus Eradication. Whitcomb E, Choi WT, Jerome KR, Cook L, Landis C, Ahn J, Te HS, Esfeh J, Hanouneh IA, Rayhill SC, Gibson W, Plesec T, Koo J, Wang HL, Hart J, Pai RK, Westerhoff M. Clin Gastroenterol Hepatol. 2017 Aug;15(8):1279-1285. doi: 10.1016/j.cgh.2017.04.041. Epub 2017 May 10.

June 2017. IRE1α promotes viral infection by conferring resistance to apoptosis. Fink SL, Jayewickreme TR, Molony RD, Iwawaki T, Landis CS, Lindenbach BD, Iwasaki A. Sci Signal. 2017 Jun 6;10(482). pii: eaai7814. doi: 10.1126/scisignal.aai7814.

June 2017. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. Bourlière M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, Ravendhran N, Vierling JM, Tran TT, Pianko S, Bansal MB, de Lédinghen V, Hyland RH, Stamm LM, Dvory-Sobol H, Svarovskaia E, Zhang J, Huang KC, Subramanian GM, Brainard DM, McHutchison JG, Verna EC, Buggisch P, Landis CS, Younes ZH, Curry MP, Strasser SI, Schiff ER, Reddy KR, Manns MP, Kowdley KV, Zeuzem S; POLARIS-1 and POLARIS-4 Investigators. N Engl J Med. 2017 Jun 1;376(22):2134-2146. doi: 10.1056/NEJMoa1613512.

April 2017. Sofosbuvir-based regimens for the treatment of chronic hepatitis C in severe renal dysfunction. Cox-North P, Hawkins KL, Rossiter ST, Hawley MN, Bhattacharya R, Landis CS. Hepatol Commun. 2017 Apr 18;1(3):248-255. doi: 10.1002/hep4.1035. eCollection 2017 May.

February 2017. Expanding access to transplantation with hepatitis C-positive donors: A new perspective on an old issue. Kling CE, Limaye AP, Landis CS, Sibulesky L. Clin Transplant. 2017 Feb;31(2). doi: 10.1111/ctr.12884.

December 2016. Management of Post-Liver Transplant Recurrence of Hepatitis C. Taylor J, Cox-North P, Landis CS. Drugs. 2016 Dec;76(18):1711-1717.

August 2016. High Antiviral Activity of NS5A Inhibitor ABT-530 With Paritaprevir/Ritonavir and Ribavirin Against Hepatitis C Virus Genotype 3 Infection. Poordad F, Landis CS, Asatryan A, Jackson DF, Ng TI, Fu B, Lin CW, Yao B, Kort J. Liver Int. 2016 Aug;36(8):1125-32. doi: 10.1111/liv.13067. Epub 2016 Feb 3.

May 2016. Daclatasvir With Sofosbuvir and Ribavirin for HCV Infection With Advanced Cirrhosis or Post-Liver Transplant Recurrence. Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, McPhee F, Hughes EA, Noviello S, Swenson ES. Hepatology. 2016 May;63(5):1493-505. doi: 10.1002/hep.28446. Epub 2016 Mar 7.

February 2016. Aging of liver transplant registrants and recipients: trends and impact on waitlist outcomes, post-transplantation outcomes and transplant-related survival benefit. Su F, Yu L, Berry K, Liou IW, Landis CS, Rayhill SC, Reyes JD, Ioannou GN. Gastroenterology. 2016 Feb;150(2):441-453.e6. doi: 10.1053/j.gastro.2015.10.043. Epub 2015 Oct 30.

October 2015. Liver Transplantation for Urea Cycle Disorders: Analysis of the United Network for Organ Sharing Database. Yu L, Rayhill SC, Hsu EK, Landis CS. Transplant Proc. 2015 Oct;47(8):2413-8. doi: 10.1016/j.transproceed.2015.09.020.

September 2015. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients with Advanced Liver Disease. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS Jr, Fried MW, Terrault NA, O'Leary JG, Vargas HE, Kuo A, Schiff E, Sulkowski MS, Gilroy R, Watt KD, Brown K, Kwo P, Pungpapong S, Korenblat KM, Muir AJ, Teperman L, Fontana RJ, Denning J, Arterburn S, Dvory-Sobol H, Brandt-Sarif T, Pang PS, McHutchison JG, Reddy KR, Afdhal N; SOLAR-1 Investigators. Gastroenterology. 2015 Sep;149(3):649-59. doi: 10.1053/j.gastro.2015.05.010. Epub 2015 May 15.

July 2015. Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report. Ende AR, Kim NH, Yeh MM, Harper J, Landis CS. J Med Case Rep. 2015 Jul 28;9:164. doi: 10.1186/s13256-015-0630-8.

April 2015. Liver regeneration and energetic changes in rats following hepatic radiation therapy and hepatocyte transplantation by (31)P MRSI. Landis CS, Zhou H, Liu L, Hetherington HP, Guha C. Liver Int. 2015 Apr;35(4):1145-51. doi: 10.1111/liv.12507. Epub 2014 Mar 15.

December 2010. The use of hepatitis B core antibody-positive donor livers does not appear to have a deleterious effect on graft survival in liver transplantation for hepatitis C. Rayhill S, Schwartz J, Ham J, Carithers R, Lei Y, Bhattacharya R, Liou I, Landis C, Lamaye A, Rakita R, Dick A, Healey P, Halldorson J, Bhakthavatsalam R, Perkins J, Reyes J. Transplant Proc. 2010 Dec;42(10):4141-4. doi: 10.1016/j.transproceed.2010.09.023.

June 2008. The hepatic stem cell niche: identification by label-retaining cell assay. Kuwahara R, Kofman AV, Landis CS, Swenson ES, Barendswaard E, Theise ND. Hepatology. 2008 Jun;47(6):1994-2002. doi: 10.1002/hep.22218.

November 2006. Noninvasive evaluation of liver repopulation by transplanted hepatocytes using 31P MRS imaging in mice. Landis CS, Yamanouchi K, Zhou H, Mohan S, Roy-Chowdhury N, Shafritz DA, Koretsky A, Roy-Chowdhury J, Hetherington HP, Guha C. Hepatology. 2006 Nov;44(5):1250-8.

October 2000. Determination of the MRI contrast agent concentration time course in vivo following bolus injection: effect of equilibrium transcytolemmal water exchange. Landis CS, Li X, Telang FW, Coderre JA, Micca PL, Rooney WD, Latour LL, Vétek G, Pályka I, Springer CS Jr. Magn Reson Med. 2000 Oct;44(4):563-74.

September 1999. Equilibrium transcytolemmal water-exchange kinetics in skeletal muscle in vivo. Landis CS, Li X, Telang FW, Molina PE, Palyka I, Vetek G, Springer CS Jr. Magn Reson Med. 1999 Sep;42(3):467-78.

Contact Info
Education

Advanced Transplant Hepatology Fellowship, Univeristy of Washington, School of Medicine, Seattle, WA

Clinical Gastroenterology Fellow, Montefiore Medical Center, Bronx, NY

Research Fellow, Marion Bessin Liver Center, Albert Einstein College of Medicine, Bronx, NY

Residency, Montefiore Medical Center, Bronx, NY

M.D., State University of New York, Stony Brook, NY

Ph.D., Physical Chemistry, State University of New York, Stony Brook, NY

Undergraduate Education, B.S. in Chemistry, California State Polytechnic University, Pomona, CA

©2016-2018 University of Washington Division of Gastroenterology
1959 NE Pacific St., Box 356424, Seattle, WA 98195-6424
Contact Us | Privacy | Terms | Copyright & Disclaimer